Beam Therapeutics Inc.
BEAM- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001745999
In the last 90 days, Beam Therapeutics Inc. insiders filed 0 open-market purchases and 2 sales; 277 institutions reported holding it in 13F filings for Q2 2026, worth $3.75B in total; superinvestors ARK Invest and Duquesne Family Office hold it.
Q1 2024 vs. Q4 2023
How the institutions holding Beam Therapeutics Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Of which not filed for Q1 2024 | Q1 2024 | Change |
|---|---|---|---|---|
| Holders | 185 | 1 | 221 | +37 |
| Shares | 68.9M | 1.10K | 70.3M | +1.41M (+2.1%) |
| Value | $1.88B | $30.1K | $2.32B | +$447.0M (+23.8%) |
1 institution that held it in Q4 2023 haven't filed for Q1 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (55)
Institutions that held Beam Therapeutics Inc. at the end of Q1 2024 but not at the end of Q4 2023.
Sold out (18)
Institutions that held Beam Therapeutics Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Tang Capital Management LLC | 350,000 | $9.53M |
| Eventide Asset Management, LLC | 261,360 | $7.11M |
| Candriam Luxembourg S.C.A. | 212,665 | $5.79M |
| Harbor Capital Advisors, Inc. | 34,918 | $950.5K |
| Caxton Associates LP | 18,703 | $509.1K |
| Corton Capital Inc. | 11,903 | $324.0K |
| CIBC World Markets Inc. | 10,181 | $277.0K |
| Capital Impact Advisors, LLC | 8,229 | $224.0K |
| Virtus Investment Advisers, Inc. | 3,049 | $83.0K |
| Advisory Services Network, LLC | 476 | $13.0K |
| Virtus Fund Advisers, LLC | 467 | $12.7K |
| Newbridge Financial Services Group, Inc. | 250 | $6.80K |
| Itau Unibanco Holding S.A. | 236 | $6.42K |
| Glassman Wealth Services | 120 | $3.27K |
| Northwestern Mutual Wealth Management Co | 50 | $1.36K |
| Cutler Group LP | 50 | $1.00K |
| Cape Investment Advisory, Inc. | 31 | $844 |
| Crewe Advisors LLC | 6 | $164 |
Not filed for Q1 2024 yet (1)
Institutions that held Beam Therapeutics Inc. at the end of Q4 2023 and haven't filed a 13F for Q1 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Fairfield Financial Advisors, LTD | 1,105 | $30.1K |